Bio‐Adrenomedullin Predicts Death and Major Adverse Cardiovascular Events in Cardiac Amyloidosis: A Cross‐Continental Multicenter Study
Bio-ADM is a promising prognostic biomarker, especially in cardiac transthyretin amyloidosis, where it improved risk stratification when added to established staging systems. Further research is needed to clarify its role as part of staging systems for cardiac immunoglobulin light chain amyloidosis.
Authors
- Oliver Hartmann (ORCID: https://orcid.org/0000-0002-5663-645X)
- Joshua D. Mitchell (ORCID: https://orcid.org/0000-0001-7371-5742)
- Birte Arlt (ORCID: https://orcid.org/0000-0002-6665-4037)
- Maximilian Leo Müller (ORCID: https://orcid.org/0000-0002-6281-9754)
- F Knebel
- Ulf Landmesser (ORCID: https://orcid.org/0000-0002-0214-3203)
- Katrin Hahn (ORCID: https://orcid.org/0000-0002-6013-0072)
- Janin Schulte (ORCID: https://orcid.org/0000-0002-6529-3882)
- Kaitlin MS Moore
- Kenichi Tsujita
- Seiji Takashio
- Yasuhiro Izumiya
- Bettina Heidecker
Institutions
- Washington University in St. Louis (US)
- Humboldt-Universität zu Berlin (DE)
- Sana Klinikum Lichtenberg (DE)
- Deutsches Herzzentrum der Charité (DE)
- German Centre for Cardiovascular Research (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Kumamoto University (JP)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1161/jaha.125.043736
- Citations
- 1
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.81